Surmodics price target raised to $71 from $70 at Barrington

Barrington raised the firm’s price target on Surmodics to $71 from $70 and keeps an Outperform rating on the shares. The company’s Q2 financial results were much better than expected as new products are gaining traction, the analyst tells investors in a research note.